GYRE Stock Analysis: Buy, Sell, or Hold?
GYRE - Gyre Therapeutics, Inc. Common Stock
$8.09
-0.12 (-1.46%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 16, 2026
Get Alerted When GYRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GYRE shows positive signals but monitor for confirmation. Market pricing in 1.7% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: GYRE shows positive signals but monitor for confirmation. Market pricing in 1.7% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: GYRE is currently trading at $8.09, which is considered extended relative to its 30-day fair value range of $7.20 to $8.05. The stock's valuation (Forward PE: 44.1) is in line with its historical norms (41.9). At these levels, the market is pricing in 1.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GYRE is showing sideways momentum. Immediate support is located at $7.53, while resistance sits at $8.38.
Market Sentiment: GYRE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.00 (+122.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GYRE is showing sideways momentum. Immediate support is located at $7.53, while resistance sits at $8.38.
Market Sentiment: GYRE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.00 (+122.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$7.20 -
$8.05
Company Quality Score
60/100
(BUY)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
64.2%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 122.5% below Wall St target ($18.00)
- NEUTRAL: Market pricing in 1.7% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$7.20 -
$8.05
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$0.86
(10.6%)
Support & Resistance Levels
Support Level
$7.53
Resistance Level
$8.38
Current Trend
Sideways
Fundamental Context
Forward P/E (Next Year Est.)
44.14
Wall Street Target
$18.00
(+122.5%)
Revenue Growth (YoY)
19.9%
Earnings Growth (YoY)
166.2%
Profit Margin
6.2%
Valuation Premium vs History
+1.7% premium
PE vs Historical
44.1 vs 41.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.7%
(market-implied from PE analysis)
1-Year Target
$8.23
(+2%)
2-Year Target
$8.37
(+3%)
3-Year Target
$8.51
(+5%)
3-Yr Target (if PE normalizes)
(PE: 44→42)
PE COMPRESSION
$8.08
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 44.1, Growth: 22.2%)
$14.76
(+83%)
Base:
(SPY PE: 22.3, Growth: 22.2%)
$7.46
(-8%)
Bear:
(PE: 19.0, Growth: 22.2%)
$6.34
(-22%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (81x PE), but valuation improves significantly next year (44x PE) as earnings recover.
Forward PE: 80.65 | Forward EPS (Implied): $0.10
Bull Case
$9.77
(+21%)
Analyst growth 15.0%, PE expands to 84.7
Base Case
$8.09
(0%)
Market implied 0.0%, PE stable at 80.7
Bear Case
$6.19
(-24%)
Severe decline -15.0%, PE contracts to 72.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: February 01, 2026 1:33 PM ET
Data refreshes hourly during market hours. Next update: 2:33 PM
Data refreshes hourly during market hours. Next update: 2:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GYRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$112 | 52 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$93 | 59 HOLD |
|
RNA
Avidity Biosciences Inc |
STRONG BUY
15 analysts |
$75 | 62 BUY |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$108 | 56 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$34 | 51 HOLD |
Advanced GYRE Option Strategies
Professional options setups generated by AI based on today's GYRE price and gamma walls.
